News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
219,020 Results
Type
Article (18631)
Company Profile (160)
Press Release (200229)
Section
Business (61744)
Career Advice (197)
Deals (8984)
Drug Delivery (52)
Drug Development (34049)
Employer Resources (33)
FDA (6746)
Job Trends (6251)
News (112257)
Policy (11321)
Tag
Academia (1578)
Alliances (17688)
Alzheimer's disease (532)
Approvals (6731)
Artificial intelligence (72)
Bankruptcy (51)
Best Places to Work (5924)
Biotechnology (119)
Breast cancer (68)
Cancer (558)
Cardiovascular disease (56)
Career advice (176)
CAR-T (39)
Cell therapy (120)
Clinical research (27599)
Collaboration (219)
Compensation (82)
COVID-19 (1062)
C-suite (57)
Cystic fibrosis (47)
Data (682)
Diabetes (82)
Diagnostics (2139)
Drug pricing (47)
Earnings (18319)
Events (32166)
Executive appointments (166)
FDA (7032)
Funding (149)
Gene editing (48)
Gene therapy (116)
GLP-1 (326)
Government (1569)
Healthcare (7612)
Infectious disease (1104)
Inflammatory bowel disease (81)
IPO (4296)
Job creations (721)
Job search strategy (168)
Layoffs (117)
Legal (1784)
Lung cancer (83)
Manufacturing (77)
Medical device (2538)
Medtech (2539)
Mergers & acquisitions (4770)
Metabolic disorders (233)
Neuroscience (663)
NextGen Class of 2024 (2125)
Non-profit (1693)
Northern California (721)
Obesity (147)
Opinion (65)
Patents (39)
People (21856)
Phase I (7627)
Phase II (11164)
Phase III (10790)
Pipeline (220)
Postmarket research (1438)
Preclinical (3104)
Radiopharmaceuticals (138)
Rare diseases (133)
Real estate (1534)
Regulatory (8628)
Research institute (1348)
Southern California (542)
Startups (1355)
United States (6013)
Vaccines (235)
Weight loss (93)
Date
Today (96)
Last 7 days (193)
Last 30 days (1421)
Last 365 days (15620)
2024 (14654)
2023 (16782)
2022 (20984)
2021 (21763)
2020 (19914)
2019 (17132)
2018 (12872)
2017 (12103)
2016 (11277)
2015 (12173)
2014 (8584)
2013 (7057)
2012 (7130)
2011 (7071)
2010 (5707)
Location
Africa (235)
Asia (14787)
Australia (2101)
California (1492)
Canada (418)
China (136)
Colorado (53)
Connecticut (83)
Delaware (49)
Europe (32955)
Florida (208)
Georgia (42)
Illinois (142)
Indiana (117)
Japan (54)
Maryland (196)
Massachusetts (1332)
Minnesota (52)
New Jersey (556)
New York (439)
North Carolina (347)
Northern California (721)
Ohio (57)
Pennsylvania (329)
South America (296)
Southern California (542)
Texas (149)
Utah (47)
Washington State (191)
219,020 Results for "plos medicine".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR) announced today the publication of its clinical validation of a novel drug-specific DRP®-companion diagnostic (CDx) for dovitinib in the peer-reviewed journal PLOS ONE.
August 30, 2023
·
8 min read
Biotech Bay
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
Jaguar Health, Inc. announced that a dog study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with the irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor neratinib has been published in the peer-reviewed journal PLOS ONE.
January 25, 2024
·
12 min read
Press Releases
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
July 19, 2024
·
3 min read
BioMidwest
Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE
The higher the level of a marker of inflammation in circulating blood, the greater the risk of dying from a range of medical disorders, according to a new study published in PLOS ONE.
August 2, 2023
·
7 min read
Biotech Bay
GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100Paper in PLOS ONE Reinforces Potential for Combination Therapy in Hematological Malignancies
GPCR Therapeutics, Inc., a clinical stage international biopharmaceutical company with an innovative approach to developing cancer therapeutics based on targeting G Protein Coupled Receptors pairs, announces publication of a research paper in PLOS ONE.
October 26, 2023
·
4 min read
Pancreatic cancer
Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts
Jefferies analyst Kelly Shi in a Sunday note to investors said that both data drops for Revolution Medicines’ experimental RAS inhibitors are positive and could be “synergistic” in the first-line setting for pancreatic ductal adenocarcinoma.
October 28, 2024
·
2 min read
·
Tristan Manalac
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
·
2 min read
·
Kate Goodwin
XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event
XNK Therapeutics AB announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.
February 8, 2024
·
1 min read
Gene Editing
Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline
In an effort to expand its cash runway beyond 12 months, Prime Medicine has signed a deal with Bristol Myers Squibb worth a potential $3.5 billion, while also streamlining its pipeline to trim costs.
September 30, 2024
·
2 min read
·
Annalee Armstrong
Rare Diseases
Biopharma Entrepreneurs Make Business Case for Personalized Genetic Medicines
Experts say the time is now to develop and provide widespread access to genetic medicines for the rarest diseases. What’s more, they say it is a moral imperative.
August 7, 2024
·
6 min read
·
Heather McKenzie
1 of 21,902
Next
